ARQT insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 79% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 11 officers and directors who sold. 15 are left out

Left out: Todd Watanabe, Bhaskar Chaudhuri, Christopher Peetz, Larry Edwards, Masaru Matsuda, Howard Welgus, Patrick Burnett, Patrick Heron, Latha Vairavan, Keith Leonard, Sue-Jean Lin, Halley Gilbert, Neha Krishnamohan, Terrie Curran and Amit Munshi (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Todd Watanabe

Reporting Person's title: President and Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.4MDisclosed plan

Howard Welgus

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.2MDisclosed plan

Masaru Matsuda

Reporting Person's title: EVP, Chief Legal Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.2MDisclosed plan

Patrick Burnett

Reporting Person's title: EVP, Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.0M78% planned, 2% to cover taxes 20% no plan disclosed

Keith Leonard

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$997KDisclosed plan

All 11 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 16, 2026Masaru Matsuda sold 3.7K shares ($92K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Masaru Matsuda Reporting Person's title: EVP, Chief Legal Officer	3,674	$25.00	n/a	n/a	Sep 16, 2026	Sep 18, 2026

Outside holders, reported separately

Patrick Heron reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Arcutis Biotherapeutics, Inc. CEO selling stock?

Yes. Todd Watanabe sold 166K shares ($4.4M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Arcutis Biotherapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 79% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 0.3% were to cover taxes and 21% had no disclosed plan. A trading plan schedules sales in advance.

Are any Arcutis Biotherapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold11 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Todd Watanabe Reporting Person's title: President and Chief Executive Officer, Director	$4.4M 166K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Howard Welgus Director	$2.2M 86K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Masaru Matsuda Reporting Person's title: EVP, Chief Legal Officer	$2.2M 87K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Patrick Burnett Reporting Person's title: EVP, Chief Medical Officer	$2.0M 78K shares	Not confirmed share of stake is being verified. Why	78% under a disclosed plan, 2% to cover taxes 20% no plan disclosed
Keith Leonard Director	$997K 39K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Terrie Curran Director	$984K 39K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Neha Krishnamohan Director	$939K 41K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Sue-Jean Lin Director	$899K 30K shares	Not confirmed share of stake is being verified. Why	13% under a disclosed plan 87% no plan disclosed
Larry Edwards Reporting Person's title: EVP, Chief Commercial Officer	$878K 35K shares	Not confirmed share of stake is being verified. Why	17% under a disclosed plan 83% no plan disclosed
Halley Gilbert Director	$455K 17K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Latha Vairavan SVP Chief Financial Officer	$148K 6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Board members representing outside shareholders, reported separately: Patrick Heron. Details

The full ownership picture0 of 15 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Todd Watanabe

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Todd Watanabe are complete.

Reporting Person's title: President and Chief Executive Officer, Director

n/a

−166K

n/a

Vesting, gifts, unvested awards and holding lines for Todd Watanabe

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Todd Watanabe are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
49,823	$1.68	Mar 13, 2029	$1.2M
410,000	$3.64	Jan 12, 2034	$8.8M
396,000	$13.69	Feb 28, 2035	$4.5M
266,000	$26.97	Feb 27, 2036	$0

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Bhaskar Chaudhuri

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Bhaskar Chaudhuri are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Bhaskar Chaudhuri

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bhaskar Chaudhuri are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,052	$8.63	Jun 14, 2034	$443K
20,568	$13.50	Jun 12, 2035	$237K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Christopher Peetz

Director

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Peetz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Peetz are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
21,486	$27.78	Jul 15, 2036	$0
13,010	$27.78	Jul 15, 2036	$0

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Larry Edwards

Reporting Person's title: EVP, Chief Commercial Officer

n/a

−35K

n/a

Vesting, gifts, unvested awards and holding lines for Larry Edwards

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Larry Edwards are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
176,000	$3.64	Jan 12, 2034	$3.8M
99,000	$13.69	Feb 28, 2035	$1.1M
43,000	$13.69	Feb 28, 2035	$486K
77,000	$26.97	Feb 27, 2036	$0

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Masaru Matsuda

Reporting Person's title: EVP, Chief Legal Officer

n/a

−87K

n/a

Vesting, gifts, unvested awards and holding lines for Masaru Matsuda

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Masaru Matsuda are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
176,000	$3.64	Jan 12, 2034	$3.8M
89,000	$13.69	Feb 28, 2035	$1.0M
97,000	$26.97	Feb 27, 2036	$0

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Howard Welgus

Director

n/a

−86K

n/a

Vesting, gifts, unvested awards and holding lines for Howard Welgus

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Howard Welgus are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,144	$7.51	May 31, 2033	$142K
18,032	$8.63	Jun 14, 2034	$295K
20,568	$13.50	Jun 12, 2035	$237K
16,667	$21.23	Jun 5, 2036	$63K
6,574	$6.52	Nov 20, 2029	$121K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Patrick Burnett

Reporting Person's title: EVP, Chief Medical Officer

n/a

−78K

n/a

Vesting, gifts, unvested awards and holding lines for Patrick Burnett

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick Burnett are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
128,750	$3.64	Jan 12, 2034	$2.8M
99,000	$13.69	Feb 28, 2035	$1.1M
43,000	$13.69	Feb 28, 2035	$486K
77,000	$26.97	Feb 27, 2036	$0

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Patrick Heron

Director

n/a

Vesting, gifts, unvested awards and holding lines for Patrick Heron

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick Heron are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,052	$8.63	Jun 14, 2034	$443K
20,568	$13.50	Jun 12, 2035	$237K
16,667	$21.23	Jun 5, 2036	$63K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Latha Vairavan

SVP Chief Financial Officer

n/a

−6K

n/a

Vesting, gifts, unvested awards and holding lines for Latha Vairavan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Latha Vairavan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,500	$17.67	Mar 3, 2032	$40K
5,000	$15.82	Mar 2, 2033	$46K
43,500	$3.64	Jan 12, 2034	$929K
23,750	$13.69	Feb 28, 2035	$269K
60,000	$14.32	May 6, 2035	$641K
70,000	$26.97	Feb 27, 2036	$0

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Keith Leonard

Director

n/a

−39K

n/a

Vesting, gifts, unvested awards and holding lines for Keith Leonard

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Keith Leonard are complete; balances and unit counts will be added when the check is finished.

−4.3Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,568	$13.50	Jun 12, 2035	$237K
16,667	$21.23	Jun 5, 2036	$63K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Sue-Jean Lin

Director

n/a

−30K

n/a

Vesting, gifts, unvested awards and holding lines for Sue-Jean Lin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sue-Jean Lin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$7.51	May 31, 2033	$87K
9,000	$8.63	Jun 14, 2034	$147K
20,568	$13.50	Jun 12, 2035	$237K
16,667	$21.23	Jun 5, 2036	$63K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Halley Gilbert

Director

n/a

−17K

n/a

Vesting, gifts, unvested awards and holding lines for Halley Gilbert

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Halley Gilbert are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,052	$8.63	Jun 14, 2034	$443K
20,568	$13.50	Jun 12, 2035	$237K
16,667	$21.23	Jun 5, 2036	$63K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Neha Krishnamohan

Director

n/a

−41K

n/a

Vesting, gifts, unvested awards and holding lines for Neha Krishnamohan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Neha Krishnamohan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,568	$13.50	Jun 12, 2035	$237K
16,667	$21.23	Jun 5, 2036	$63K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Terrie Curran

Director

n/a

−39K

n/a

Vesting, gifts, unvested awards and holding lines for Terrie Curran

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Terrie Curran are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,568	$13.50	Jun 12, 2035	$237K
16,667	$21.23	Jun 5, 2036	$63K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Amit Munshi

Director

n/a

Vesting, gifts, unvested awards and holding lines for Amit Munshi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Amit Munshi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
16,502	$31.16	Dec 4, 2035	$0
6,177	$31.16	Dec 4, 2035	$0
16,667	$21.23	Jun 5, 2036	$63K

Estimate: options held × ($25.00 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Holdings and share of stake for Arcutis Biotherapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$16.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $16.2M across 624,043 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $12.8M · 79%

21%

The lighter segment is sales with no plan disclosed in the filing ($3.4M), including tax-related sales outside a plan.

No plan disclosed · $3.3M

Sales with no 10b5-1 plan and no tax reference in the filing. $984K of it is Terrie Curran. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Sue-Jean Lin, Nov 24, 2025

Taxes

$3.3M of sales (20.7%) cite tax obligations in their footnotes, $3.3M of them also under a plan. Example: Patrick Burnett, Aug 19, 2026

Charitable gifts · 4.3K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Todd Watanabe Reporting Person's title: President and Chief Executive Officer, Director	166K	$4.4M	100%	27%	Oct 28, 2025 to Aug 3, 2026
Howard Welgus Director	86K	$2.2M	100%	14%	Nov 3, 2025 to Sep 15, 2026
Masaru Matsuda Reporting Person's title: EVP, Chief Legal Officer	87K	$2.2M	100%	14%	Nov 3, 2025 to Sep 16, 2026
Patrick Burnett Reporting Person's title: EVP, Chief Medical Officer	78K	$2.0M	78%	12%	Nov 3, 2025 to Aug 19, 2026
Keith Leonard Director	39K	$997K	100%	6%	Mar 2, 2026 to Mar 2, 2026
Terrie Curran Director	39K	$984K	0%	6%	Aug 20, 2026 to Aug 27, 2026
Neha Krishnamohan Director	41K	$939K	100%	6%	Nov 13, 2025 to Nov 13, 2025
Sue-Jean Lin Director	30K	$899K	13%	6%	Nov 24, 2025 to Jun 15, 2026
Larry Edwards Reporting Person's title: EVP, Chief Commercial Officer	35K	$878K	17%	5%	Nov 6, 2025 to Mar 2, 2026
Halley Gilbert Director	17K	$455K	0%	3%	Nov 20, 2025 to Nov 20, 2025
Latha Vairavan SVP Chief Financial Officer	6K	$148K	100%	0.9%	Nov 3, 2025 to May 11, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$1.0M	$1.0M	$0	$0
Nov 2025	$5.8M	$3.8M	$0	$2.0M
Dec 2025	$735K	$735K	$0	$0
Jan 2026	$362K	$362K	$0	$0
Feb 2026	$2.3M	$2.3M	$0	$0
Mar 2026	$2.7M	$2.7M	$0	$0
Apr 2026	$239K	$239K	$0	$0
May 2026	$493K	$493K	$0	$0
Jun 2026	$237K	$237K	$0	$0
Jul 2026	$127K	$127K	$0	$0
Aug 2026	$1.7M	$295K	$46K	$1.4M
Sep 2026	$456K	$456K	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 16, 2025	Sold	Held Oct 16, 2026	Still held
Patrick Heron ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Patrick Heron are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Patrick Heron Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick Heron are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $16.2M sold, after almost none in the past 5 years. 11 insiders sold; the average is 8 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	624K	11	$16.2M
Oct 16, 2025 1 year earlier	601K	8	$8.4M
Oct 16, 2024 2 years earlier	248K	7	$2.3M
Oct 17, 2023 3 years earlier	75K	9	$1.1M
Oct 17, 2022 4 years earlier	96K	8	$2.0M
Oct 17, 2021 5 years earlier	161K	7	$4.8M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty15 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Arcutis Biotherapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology442 filings on record, 68 filed in the 12-month period, and how we read them

All 442 Forms 3, 4 and 5 on record for Arcutis Biotherapeutics, Inc. (SEC CIK 1787306), filed from Jan 30, 2020 to Sep 18, 2026; 68 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (15)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
David Topper	Apr 3, 2025	182,774 shares, last reported balance as of Apr 2, 2025
Matthew Moore	May 3, 2024	145,505 shares, last reported balance as of May 2, 2024
John Smither	Feb 15, 2024	152,757 shares, last reported balance as of Feb 13, 2024
Kenneth Lock	Mar 8, 2023	63,429 shares, last reported balance as of Mar 6, 2023
Patricia Turney	Mar 8, 2023	62,862 shares, last reported balance as of Mar 6, 2023
David Osborne	Mar 8, 2023	393,810 shares, last reported balance as of Mar 6, 2023
Scott Burrows	Mar 8, 2023	59,115 shares, last reported balance as of Mar 6, 2023
ORBIMED ADVISORS LLC	Jun 28, 2022	3,949,679 shares, last reported balance as of Jun 24, 2022
Joseph Turner	Jun 3, 2022	No balance on record
Ricky Sun	Jun 11, 2021	No balance on record
Jonathan Silverstein	Oct 6, 2020	902,286 shares, last reported balance as of Oct 2, 2020
Jonathan Silverstein	Oct 6, 2020	4,267,564 shares, last reported balance as of Oct 2, 2020
Daniel Estes	Mar 3, 2020	No balance on record
Bain Capital Life Sciences Investors, LLC	Feb 6, 2020	10,490,069 shares, last reported balance as of Feb 4, 2020
Alexander Asam	Jan 30, 2020	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Arcutis Biotherapeutics, Inc. insiders sold $16.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Arcutis Biotherapeutics, Inc. CEO selling stock?

Why are Arcutis Biotherapeutics, Inc. insiders selling?

Are any Arcutis Biotherapeutics, Inc. insiders buying?

The evidence

No plan disclosed · $3.3M

Taxes

Charitable gifts · 4.3K shares

Sales by month